Table Info

Table 1.

Physio-chemical properties of psoralidin

Descriptor	Value
Empirical formula	C₂₀H₁₆O₅
Chemical name	3,9-dihydroxy-2-prenylcoumestan
Molecular weight	336.3 g/mol
Polar surface area	79.9 Å²
Physical form	Solid
Melting point	290–292°C
LogP	4.6123
Rotable bonds	2
Hydrogen acceptors	5
Hydrogen donors	2
Solubility in water	Poor
Bioavailability score	0.55
BBB permeant	No
Lipinski’s violation	0

BBB: blood brain barrier. Source: PubChem, pkCSM [74] and SwissADME [75]

Declarations

Author contributions

ACB: Conceptualization, Funding acquisition, Project administration, Resources, Supervision, Validation, Writing—review & editing. TT and ACB: Data curation, Visualization, Writing—original draft. TT, AC, DJ, UJ, NA, and CCK: Formal analysis. TT, DJ, AC, and UJ: Investigation. TT, UJ, DJ, AC, and NA: Methodology.

Conflicts of interest

The authors declare that there are no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

The datasets that support the findings of this study are available from the corresponding author upon reasonable request.

Funding

This work was funded by Indian Council of Medical Research-India Cancer Research Consortium (ICMR-ICRC) [No.5/13/4/ACB/ICRC/2020/NCD-III], ICMR AdHOC [2021-10573/GENOMIC/ADHOC-BMS]; Central Council for Research in Homeopathy (CCRH) [F.No.17-30/2023-24/CCRH/Tech/Coll./DU Cervical Cancer Phase-II/498]; Institution of Eminence, University of Delhi [Ref. No./IoE/2023-24/12/FRP] to ACB is thankfully acknowledged. In addition to the above funding support, the research has received several non-funding financial support such as Senior Research Fellowship to TT [764/(CSIR-UGC NET JUNE 2019)] by University Grants Commission (UGC), and Senior Research Fellowship to DJ [09/0045/(11635)/2021-EMR-1] and AC [09/0045(12901)/2022-EMR-1] by Council of Scientific and Industrial Research (CSIR). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev. 2003;16:1–17. [DOI] [PubMed] [PMC]

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–49. [DOI] [PubMed]

Adegoke O, Kulasingam S, Virnig B. Cervical cancer trends in the United States: a 35-year population-based analysis. J Womens Health (Larchmt). 2012;21:1031–7. [DOI] [PubMed] [PMC]

Hall MT, Simms KT, Lew J, Smith MA, Brotherton JM, Saville M, et al. The projected timeframe until cervical cancer elimination in Australia: a modelling study. Lancet Public Health. 2019;4:e19–27. [DOI] [PubMed]

Sankaranarayanan R. Screening for cancer in low- and middle-income countries. Ann Glob Health. 2014;80:412–7. [DOI] [PubMed]

Balasubramaniam G, Gaidhani RH, Khan A, Saoba S, Mahantshetty U, Maheshwari A. Survival rate of cervical cancer from a study conducted in India. Indian J Med Sci. 2021;73:203–11. [DOI]

Brisson M, Kim JJ, Canfell K, Drolet M, Gingras G, Burger EA, et al. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet. 2020;395:575–90. [DOI] [PubMed] [PMC]

Arbyn M, Weiderpass E, Bruni L, Sanjosé Sd, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8:e191–203. [DOI] [PubMed] [PMC]

Hausen Hz. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst. 2000;92:690–8. [DOI] [PubMed]

10.

Harro CD, Pang YY, Roden RB, Hildesheim A, Wang Z, Reynolds MJ, et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst. 2001;93:284–92. [DOI] [PubMed]

11.

Mohanty G, Ghosh SN. Risk factors for cancer of cervix, status of screening and methods for its detection. Arch Gynecol Obstet. 2015;291:247–9. [DOI] [PubMed]

12.

Gheit T. Mucosal and Cutaneous Human Papillomavirus Infections and Cancer Biology. Front Oncol. 2019;9:355. [DOI] [PubMed] [PMC]

13.

Muñoz N, Bosch FX, Sanjosé Sd, Herrero R, Castellsagué X, Shah KV, et al.; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518–27. [DOI] [PubMed]

14.

Das BC, Sharma JK, Gopalkrishna V, Das DK, Singh V, Gissmann L, et al. A high frequency of human papillomavirus DNA sequences in cervical carcinomas of Indian women as revealed by Southern blot hybridization and polymerase chain reaction. J Med Virol. 1992;36:239–45. [DOI] [PubMed]

15.

Siebers AG, Linden Hvd, Vedder JEM, Bekkers RLM, Melchers WLG, Bulten J. Presence of koilocytosis in low-grade smears of high-risk HPV-positive women is a negative predictor for cervical intraepithelial neoplasia grade 3 or more. Cytopathology. 2018;29:275–80. [DOI] [PubMed]

16.

Shanmugasundaram S, You J. Targeting Persistent Human Papillomavirus Infection. Viruses. 2017;9:229. [DOI] [PubMed] [PMC]

17.

Matsumoto K, Oki A, Furuta R, Maeda H, Yasugi T, Takatsuka N, et al.; Japan HPV And Cervical Cancer Study Group. Predicting the progression of cervical precursor lesions by human papillomavirus genotyping: a prospective cohort study. Int J Cancer. 2011;128:2898–910. [DOI] [PubMed]

18.

Williams VM, Filippova M, Soto U, Duerksen-Hughes PJ. HPV-DNA integration and carcinogenesis: putative roles for inflammation and oxidative stress. Future Virol. 2011;6:45–57. [DOI] [PubMed] [PMC]

19.

Thomas JT, Laimins LA. Human papillomavirus oncoproteins E6 and E7 independently abrogate the mitotic spindle checkpoint. J Virol. 1998;72:1131–7. [DOI] [PubMed] [PMC]

20.

Dyson N, Howley PM, Münger K, Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science. 1989;243:934–7. [DOI] [PubMed]

21.

Burmeister CA, Khan SF, Schäfer G, Mbatani N, Adams T, Moodley J, et al. Cervical cancer therapies: Current challenges and future perspectives. Tumour Virus Res. 2022;13:200238. [DOI] [PubMed] [PMC]

22.

Greggi S, Casella G, Scala F, Falcone F, Visconti S, Scaffa C. Surgical Management of Early Cervical Cancer: When Is Laparoscopic Appropriate? Curr Oncol Rep. 2020;22:7. [DOI] [PubMed]

23.

Nguyen VT, Winterman S, Playe M, Benbara A, Zelek L, Pamoukdjian F, et al. Dose-Intense Cisplatin-Based Neoadjuvant Chemotherapy Increases Survival in Advanced Cervical Cancer: An Up-to-Date Meta-Analysis. Cancers (Basel). 2022;14:842. [DOI] [PubMed] [PMC]

24.

Chargari C, Peignaux K, Escande A, Renard S, Lafond C, Petit A, et al. Radiotherapy of cervical cancer. Cancer Radiother. 2022;26:298–308. [DOI] [PubMed]

25.

Kirchheiner K, Nout RA, Czajka-Pepl A, Ponocny-Seliger E, Sturdza AE, Dimopoulos JC, et al. Health related quality of life and patient reported symptoms before and during definitive radio(chemo)therapy using image-guided adaptive brachytherapy for locally advanced cervical cancer and early recovery - a mono-institutional prospective study. Gynecol Oncol. 2015;136:415–23. [DOI] [PubMed]

26.

Liao T, Kaufmann AM, Qian X, Sangvatanakul V, Chen C, Kube T, et al. Susceptibility to cytotoxic T cell lysis of cancer stem cells derived from cervical and head and neck tumor cell lines. J Cancer Res Clin Oncol. 2013;139:159–70. [DOI] [PubMed]

27.

Wendel Naumann R, Leath CA 3rd. Advances in immunotherapy for cervical cancer. Curr Opin Oncol. 2020;32:481–7. [DOI] [PubMed] [PMC]

28.

Mutlu L, Tymon-Rosario J, Harold J, Menderes G. Targeted treatment options for the management of metastatic/persistent and recurrent cervical cancer. Expert Rev Anticancer Ther. 2022;22:633–45. [DOI] [PubMed]

29.

Inturi R, Jemth P. CRISPR/Cas9-based inactivation of human papillomavirus oncogenes E6 or E7 induces senescence in cervical cancer cells. Virology. 2021;562:92–102. [DOI] [PubMed]

30.

Gu W, Yeo E, McMillan N, Yu C. Silencing oncogene expression in cervical cancer stem-like cells inhibits their cell growth and self-renewal ability. Cancer Gene Ther. 2011;18:897–905. [DOI] [PubMed]

31.

Putral LN, Bywater MJ, Gu W, Saunders NA, Gabrielli BG, Leggatt GR, et al. RNA interference against human papillomavirus oncogenes in cervical cancer cells results in increased sensitivity to cisplatin. Mol Pharmacol. 2005;68:1311–9. [DOI] [PubMed]

32.

Mahata S, Bharti AC, Shukla S, Tyagi A, Husain SA, Das BC. Berberine modulates AP-1 activity to suppress HPV transcription and downstream signaling to induce growth arrest and apoptosis in cervical cancer cells. Mol Cancer. 2011;10:39. [DOI] [PubMed] [PMC]

33.

Singh T, Chhokar A, Thakur K, Aggarwal N, Pragya P, Yadav J, et al. Targeting Aberrant Expression of STAT3 and AP-1 Oncogenic Transcription Factors and HPV Oncoproteins in Cervical Cancer by Berberis aquifolium. Front Pharmacol. 2021;12:757414. [DOI] [PubMed] [PMC]

34.

Mahata S, Maru S, Shukla S, Pandey A, Mugesh G, Das BC, et al. Anticancer property of Bryophyllum pinnata (Lam.) Oken. leaf on human cervical cancer cells. BMC Complement Altern Med. 2012;12:15. [DOI] [PubMed] [PMC]

35.

Mahata S, Pandey A, Shukla S, Tyagi A, Husain SA, Das BC, et al. Anticancer activity of Phyllanthus emblica Linn. (Indian gooseberry): inhibition of transcription factor AP-1 and HPV gene expression in cervical cancer cells. Nutr Cancer. 2013;65:88–97. [DOI] [PubMed]

36.

Singh T, Aggarwal N, Thakur K, Chhokar A, Yadav J, Tripathi T, et al. Evaluation of Therapeutic Potential of Selected Plant-Derived Homeopathic Medicines for their Action against Cervical Cancer. Homeopathy. 2023;112:262–74. [DOI] [PubMed]

37.

Chen Y, Zhu Y, Wu J. Prognosis of Early Stage Cervical Cancer According to Patterns of Recurrence. Cancer Manag Res. 2021;13:8131–6. [DOI] [PubMed] [PMC]

38.

Zhang T, Zhuang L, Muaibati M, Wang D, Abasi A, Tong Q, et al. Identification of cervical cancer stem cells using single-cell transcriptomes of normal cervix, cervical premalignant lesions, and cervical cancer. EBioMedicine. 2023;92:104612. [DOI] [PubMed] [PMC]

39.

Chen X, Lin L, Wu Q, Li S, Wang H, Sun Y. Tumor Necrosis Factor- α Promotes the Tumorigenesis, Lymphangiogenesis, and Lymphatic Metastasis in Cervical Cancer via Activating VEGFC-Mediated AKT and ERK Pathways. Mediators Inflamm. 2023;2023:5679966. [DOI] [PubMed] [PMC]

40.

Bernard X, Robinson P, Nominé Y, Masson M, Charbonnier S, Ramirez-Ramos JR, et al. Proteasomal degradation of p53 by human papillomavirus E6 oncoprotein relies on the structural integrity of p53 core domain. PLoS One. 2011;6:e25981. [DOI] [PubMed] [PMC]

41.

Pal A, Kundu R. Human Papillomavirus E6 and E7: The Cervical Cancer Hallmarks and Targets for Therapy. Front Microbiol. 2020;10:3116. [DOI] [PubMed] [PMC]

42.

Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell. 1993;75:495–505. [DOI] [PubMed]

43.

Li J, Wang H. H3K27ac-activated EGFR-AS1 promotes cell growth in cervical cancer through ACTN4-mediated WNT pathway. Biol Direct. 2022;17:3. [DOI] [PubMed] [PMC]

44.

McIntyre JB, Wu JS, Craighead PS, Phan T, Köbel M, Lees-Miller SP, et al. PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy. Gynecol Oncol. 2013;128:409–14. [DOI] [PubMed]

45.

Massihnia D, Avan A, Funel N, Maftouh M, Krieken Av, Granchi C, et al. Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer. J Hematol Oncol. 2017;10:9. [DOI] [PubMed] [PMC]

46.

Bahrami A, Hasanzadeh M, Hassanian SM, ShahidSales S, Ghayour-Mobarhan M, Ferns GA, et al. The Potential Value of the PI3K/Akt/mTOR Signaling Pathway for Assessing Prognosis in Cervical Cancer and as a Target for Therapy. J Cell Biochem. 2017;118:4163–9. [DOI] [PubMed]

47.

Xu M, Katzenellenbogen RA, Grandori C, Galloway DA. NFX1 plays a role in human papillomavirus type 16 E6 activation of NFkappaB activity. J Virol. 2010;84:11461–9. [DOI] [PubMed] [PMC]

48.

Nakahara T, Tanaka K, Ohno S, Egawa N, Yugawa T, Kiyono T. Activation of NF-κB by human papillomavirus 16 E1 limits E1-dependent viral replication through degradation of E1. J Virol. 2015;89:5040–59. [DOI] [PubMed] [PMC]

49.

James MA, Lee JH, Klingelhutz AJ. Human papillomavirus type 16 E6 activates NF-kappaB, induces cIAP-2 expression, and protects against apoptosis in a PDZ binding motif-dependent manner. J Virol. 2006;80:5301–7. [DOI] [PubMed] [PMC]

50.

Liu F, Dai M, Xu Q, Zhu X, Zhou Y, Jiang S, et al. SRSF10-mediated IL1RAP alternative splicing regulates cervical cancer oncogenesis via mIL1RAP-NF-κB-CD47 axis. Oncogene. 2018;37:2394–409. [DOI] [PubMed] [PMC]

51.

Liu D, Miao H, Zhao Y, Kang X, Shang S, Xiang W, et al. NF-κB potentiates tumor growth by suppressing a novel target LPTS. Cell Commun Signal. 2017;15:39. [DOI] [PubMed] [PMC]

52.

Morgan EL, Macdonald A. Autocrine STAT3 activation in HPV positive cervical cancer through a virus-driven Rac1-NFκB-IL-6 signalling axis. PLoS Pathog. 2019;15:e1007835. [DOI] [PubMed] [PMC]

53.

Deng S, Yuan P, Sun J. The role of NF-κB in carcinogenesis of cervical cancer: opportunities and challenges. Mol Biol Rep. 2024;51:538. [DOI] [PubMed]

54.

Maliekal TT, Bajaj J, Giri V, Subramanyam D, Krishna S. The role of Notch signaling in human cervical cancer: implications for solid tumors. Oncogene. 2008;27:5110–4. [DOI] [PubMed]

55.

Rodrigues C, Joy LR, Sachithanandan SP, Krishna S. Notch signalling in cervical cancer. Exp Cell Res. 2019;385:111682. [DOI] [PubMed]

56.

Muthuramalinga K, Cho M & Kim Y. Role of NADPH oxidase and its therapeutic intervention in TGF-β-mediated EMT progression: an in vitro analysis on HeLa cervical cancer cells. Appl Biol Chem. 2020;63:4. [DOI]

57.

Kim YM, Muthuramalingam K, Cho M. Redox Regulation of NOX Isoforms on FAK^(Y397)/SRC^(Y416) Phosphorylation Driven Epithelial-to-Mesenchymal Transition in Malignant Cervical Epithelial Cells. Cells. 2020;9:1555. [DOI] [PubMed] [PMC]

58.

Chen L, Chen S, Sun P, Liu X, Zhan Z, Wang J. Psoralea corylifolia L.: a comprehensive review of its botany, traditional uses, phytochemistry, pharmacology, toxicology, quality control and pharmacokinetics. Chin Med. 2023;18:4. [DOI] [PubMed] [PMC]

59.

Zhao L, Huang C, Shan Z, Xiang B, Mei L. Fingerprint analysis of Psoralea corylifolia L. by HPLC and LC-MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;821:67–74. [DOI] [PubMed]

60.

Qiao C, Han Q, Song J, Mo S, Kong L, Kung H, et al. Chemical fingerprint and quantitative analysis of fructus psoraleae by high-performance liquid chromatography. J Sep Sci. 2007;30:813–8. [DOI] [PubMed]

61.

Yin FZ, Li L, Lu TL, Li WD, Cai BC, Yin W. Quality Assessment of Psoralea fructus by HPLC Fingerprint Coupled with Multi-components Analysis. Indian J Pharm Sci. 2015;77:715–22. [DOI] [PubMed] [PMC]

62.

Zhang Y, Chen Z, Xu X, Zhou Q, Liu X, Liao L, et al. Rapid separation and simultaneous quantitative determination of 13 constituents in Psoraleae Fructus by a single marker using high-performance liquid chromatography with diode array detection. J Sep Sci. 2017;40:4191–202. [DOI] [PubMed]

63.

Luan L, Shen X, Liu X, Wu Y, Tan M. Qualitative analysis of Psoraleae Fructus by HPLC-DAD/TOF-MS fingerprint and quantitative analysis of multiple components by single marker. Biomed Chromatogr. 2018;32:e4059. [DOI] [PubMed]

64.

Shi M, Zhang Y, Song M, Sun Y, Li C, Kang W. Screening the Marker Components in Psoralea corylifolia L. with the Aids of Spectrum-Effect Relationship and Component Knock-Out by UPLC-MS². Int J Mol Sci. 2018;19:3439. [DOI] [PubMed] [PMC]

65.

Shi M, Zhang J, Liu C, Cui Y, Li C, Liu Z, et al. Ionic Liquid-Based Ultrasonic-Assisted Extraction to Analyze Seven Compounds in Psoralea Fructus Coupled with HPLC. Molecules. 2019;24:1699. [DOI] [PubMed] [PMC]

66.

Khastgir HN, Duttagupta PC, Sengupta P. The structure of psoralidin. Tetrahedron. 1961;14:275–83. [DOI]

67.

Yang YM, Hyun JW, Sung MS, Chung HS, Kim BK, Paik WH, et al. The cytotoxicity of psoralidin from Psoralea corylifolia. Planta Med. 1996;62:353–4. [DOI] [PubMed]

68.

Mar W, Je KH, Seo EK. Cytotoxic constituents of Psoralea corylifolia. Arch Pharm Res. 2001;24:211–3. [DOI] [PubMed]

69.

Khatune NA, Islam ME, Haque ME, Khondkar P, Rahman MM. Antibacterial compounds from the seeds of Psoralea corylifolia. Fitoterapia. 2004;75:228–30. [DOI] [PubMed]

70.

Kim Y, Oh H, Kim BS, Kang T, Ko E, Han YM, et al. In vitro protein tyrosine phosphatase 1B inhibitory phenols from the seeds of Psoralea corylifolia. Planta Med. 2005;71:87–9. [DOI] [PubMed]

71.

Mukai R, Fujikura Y, Murota K, Uehara M, Minekawa S, Matsui N, et al. Prenylation enhances quercetin uptake and reduces efflux in Caco-2 cells and enhances tissue accumulation in mice fed long-term. J Nutr. 2013;143:1558–64. [DOI] [PubMed]

72.

Pahari P, Rohr J. Total synthesis of psoralidin, an anticancer natural product. J Org Chem. 2009;74:2750–4. [DOI] [PubMed] [PMC]

73.

Pahari P, Saikia UP, Das TP, Damodaran C, Rohr J. Synthesis of Psoralidin derivatives and their anticancer activity: First synthesis of Lespeflorin I1. Tetrahedron. 2016;72:3324–34. [DOI] [PubMed] [PMC]

74.

Pires DEV, Blundell TL, Ascher DB. pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures. J Med Chem. 2015;58:4066–72. [DOI] [PubMed] [PMC]

75.

Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7:42717. [DOI] [PubMed] [PMC]

76.

Baig MMV. Phytochemical and antimicrobial activity screening of seeds of Psoralea corylifolia L. Phytomedicine Plus. 2022;2:100278. [DOI]

77.

Matsuda H, Sugimoto S, Morikawa T, Matsuhira K, Mizuguchi E, Nakamura S, et al. Bioactive constituents from Chinese natural medicines. XX. Inhibitors of antigen-induced degranulation in RBL-2H3 cells from the seeds of Psoralea corylifolia. Chem Pharm Bull (Tokyo). 2007;55:106–10. [DOI] [PubMed]

78.

Matsuda H, Kiyohara S, Sugimoto S, Ando S, Nakamura S, Yoshikawa M. Bioactive constituents from Chinese natural medicines. XXXIII. Inhibitors from the seeds of Psoralea corylifolia on production of nitric oxide in lipopolysaccharide-activated macrophages. Biol Pharm Bull. 2009;32:147–9. [DOI] [PubMed]

79.

Yang HJ, Youn H, Seong KM, Yun YJ, Kim W, Kim YH, et al. Psoralidin, a dual inhibitor of COX-2 and 5-LOX, regulates ionizing radiation (IR)-induced pulmonary inflammation. Biochem Pharmacol. 2011;82:524–34. [DOI] [PubMed]

80.

Chiou W, Don M, Liao J, Wei B. Psoralidin inhibits LPS-induced iNOS expression via repressing Syk-mediated activation of PI3K-IKK-IκB signaling pathways. Eur J Pharmacol. 2011;650:102–9. [DOI] [PubMed]

81.

Ziadlou R, Barbero A, Stoddart MJ, Wirth M, Li Z, Martin I, et al. Regulation of Inflammatory Response in Human Osteoarthritic Chondrocytes by Novel Herbal Small Molecules. Int J Mol Sci. 2019;20:5745. [DOI] [PubMed] [PMC]

82.

Jiang M, Luo M, Tian K, Li Y, Sun J, Lu Y, et al. α-Glucosidase Inhibitory and Anti-Inflammatory Coumestans from the Roots of Dolichos trilobus. Planta Med. 2019;85:112–7. [DOI] [PubMed]

83.

Yi L, Li Y, Pan Y, Li J, Xu Q, Mo S, et al. Antidepressant-like effects of psoralidin isolated from the seeds of Psoralea Corylifolia in the forced swimming test in mice. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:510–9. [DOI] [PubMed]

84.

Chen Y, Cheung Y, Kong L, Ng TB, Qiao C, Mo S, et al. Transcriptional regulation of corticotrophin releasing factor gene by furocoumarins isolated from seeds of Psoralea corylifolia. Life Sci. 2008;82:1117–21. [DOI]

85.

Kim DW, Seo KH, Curtis-Long MJ, Oh KY, Oh J, Cho JK, et al. Phenolic phytochemical displaying SARS-CoV papain-like protease inhibition from the seeds of Psoralea corylifolia. J Enzyme Inhib Med Chem. 2014;29:59–63. [DOI] [PubMed]

86.

Dey D, Dey N, Ghosh S, Chandrasekaran N, Mukherjee A, Thomas J. Potential combination therapy using twenty phytochemicals from twenty plants to prevent SARS- CoV-2 infection: An in silico Approach. Virusdisease. 2021;32:108–16. [DOI] [PubMed] [PMC]

87.

Song K, Ling F, Huang A, Dong W, Liu G, Jiang C, et al. In vitro and in vivo assessment of the effect of antiprotozoal compounds isolated from Psoralea corylifolia against Ichthyophthirius multifiliis in fish. Int J Parasitol Drugs Drug Resist. 2015;5:58–64. [DOI] [PubMed] [PMC]

88.

Kim YJ, Lim H, Lee J, Jeong S. Quantitative Analysis of Psoralea corylifolia Linne and its Neuroprotective and Anti-Neuroinflammatory Effects in HT22 Hippocampal Cells and BV-2 Microglia. Molecules. 2016;21:1076. [DOI] [PubMed] [PMC]

89.

Hwang S, Lee S, Ahn S, Lee GH. Psoralidin Stimulates Expression of Immediate-Early Genes and Synapse Development in Primary Cortical Neurons. Neurochem Res. 2018;43:2460–72. [DOI] [PubMed]

90.

Gebremeskel AK, Wijerathne TD, Kim JH, Kim MJ, Seo C, Shin H, et al. Psoralea corylifolia extract induces vasodilation in rat arteries through both endothelium-dependent and -independent mechanisms involving inhibition of TRPC3 channel activity and elaboration of prostaglandin. Pharm Biol. 2017;55:2136–44. [DOI] [PubMed] [PMC]

91.

Zhai Y, Li Y, Wang Y, Cui J, Feng K, Kong X, et al. Psoralidin, a prenylated coumestan, as a novel anti-osteoporosis candidate to enhance bone formation of osteoblasts and decrease bone resorption of osteoclasts. Eur J Pharmacol. 2017;801:62–71. [DOI] [PubMed]

92.

Kong L, Ma R, Yang X, Zhu Z, Guo H, He B, et al. Psoralidin suppresses osteoclastogenesis in BMMs and attenuates LPS-mediated osteolysis by inhibiting inflammatory cytokines. Int Immunopharmacol. 2017;51:31–9. [DOI] [PubMed]

93.

Zhai Y, Wang Q, Li Y, Cui J, Feng K, Kong X, et al. The higher osteoprotective activity of psoralidin in vivo than coumestrol is attributed by its presence of an isopentenyl group and through activated PI3K/Akt axis. Biomed Pharmacother. 2018;102:1015–24. [DOI] [PubMed]

94.

Rao Z, Wang S, Wang J. Protective effects of psoralidin on IL‑1β‑induced chondrocyte apoptosis. Mol Med Rep. 2018;17:3418–24. [DOI] [PubMed]

95.

Cao H, Li C, Wang L, Ziadlou R, Grad S, Zhang Y, et al. Effect and mechanism of psoralidin on promoting osteogenesis and inhibiting adipogenesis. Phytomedicine. 2019;61:152860. [DOI] [PubMed]

96.

Hua R, Zou J, Ma Y, Wang X, Chen Y, Li Y, et al. Psoralidin prevents caffeine-induced damage and abnormal differentiation of bone marrow mesenchymal stem cells via the classical estrogen receptor pathway. Ann Transl Med. 2021;9:1245. [DOI] [PubMed] [PMC]

97.

Alalaiwe A, Hung C, Leu Y, Tahara K, Chen H, Hu K, et al. The active compounds derived from Psoralea corylifolia for photochemotherapy against psoriasis-like lesions: The relationship between structure and percutaneous absorption. Eur J Pharm Sci. 2018;124:114–26. [DOI] [PubMed]

98.

Liang Z, Chen Y, Wang Z, Wu X, Deng C, Wang C, et al. Protective effects and mechanisms of psoralidin against adriamycin-induced cardiotoxicity. J Adv Res. 2022;40:249–61. [DOI] [PubMed] [PMC]

99.

Yang Y, Lei W, Qian L, Zhang S, Yang W, Lu C, et al. Activation of NR1H3 signaling pathways by psoralidin attenuates septic myocardial injury. Free Radic Biol Med. 2023;204:8–19. [DOI] [PubMed]

100.

Prabhakar PK, Sivakumar PM. Protein Tyrosine Phosphatase 1B Inhibitors: A Novel Therapeutic Strategy for the Management of type 2 Diabetes Mellitus. Curr Pharm Des. 2019;25:2526–39. [DOI] [PubMed]

101.

Lv Y, Fu J, Jia Q, Che D, Lin Y, Han S, et al. Accurate quantification of β-hexosaminidase released from laboratory of allergic diseases 2 cells via liquid chromatography tandem mass spectrometry method. J Chromatogr A. 2018;1578:106–11. [DOI] [PubMed]

102.

Arborelius L, Owens MJ, Plotsky PM, Nemeroff CB. The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol. 1999;160:1–12. [DOI] [PubMed]

103.

Vliet VJEv, Huynh N, Palà J, Patel A, Singer A, Slater C, et al. Ubiquitin variants potently inhibit SARS-CoV-2 PLpro and viral replication via a novel site distal to the protease active site. PLoS Pathog. 2022;18:e1011065. [DOI] [PubMed] [PMC]

104.

Peacock TP, Goldhill DH, Zhou J, Baillon L, Frise R, Swann OC, et al. The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets. Nat Microbiol. 2021;6:899–909. [DOI] [PubMed]

105.

Yaseen A, Yang F, Zhang X, Li F, Chen B, Faraag AHI, et al. Ferroptosis inhibitory constituents from the fruits of Cullen corylifolium. Nat Prod Res. 2021;35:5364–68. [DOI] [PubMed]

106.

Lei W, Wu S, Zhao A, Wu Z, Ding B, Yang W, et al. Psoralidin protects against cerebral hypoxia/reoxygenation injury: Role of GAS6/Axl signaling. Phytother Res. 2022;36:2628–40. [DOI] [PubMed]

107.

Iozumi K, Hoganson GE, Pennella R, Everett MA, Fuller BB. Role of tyrosinase as the determinant of pigmentation in cultured human melanocytes. J Invest Dermatol. 1993;100:806–11. [DOI] [PubMed]

108.

Wang X, Liang Z, Liu Q, Ye X, Wu X, Deng C, et al. Identification of PIK3R5 as a hub in septic myocardial injury and the cardioprotective effects of Psoralidin. Phytomedicine. 2024;122:155146. [DOI] [PubMed]

109.

Liu X, Nam J, Song YS, Viswanath ANI, Pae AN, Kil Y, et al. Psoralidin, a coumestan analogue, as a novel potent estrogen receptor signaling molecule isolated from Psoralea corylifolia. Bioorg Med Chem Lett. 2014;24:1403–6. [DOI] [PubMed]

110.

Sun D, Ge G, Dong P, Cao Y, Fu Z, Ran R, et al. Inhibition behavior of fructus psoraleae’s ingredients towards human carboxylesterase 1 (hCES1). Xenobiotica. 2016;46:503–10. [DOI] [PubMed]

111.

Li S, Liu X, Nie Y, Yang L, Zhang C, Guo Y, et al. Psoralidin Induced Differentiation from Adipose-derived Stem Cells to Nucleus Pulposus-like Cells by TGF-β/Smad Signaling. Curr Mol Med. 2023;23:688–97. [DOI] [PubMed]

112.

Lan Q, Lu R, Chen H, Pang Y, Xiong F, Shen C, et al. MMP-13 enzyme and pH responsive theranostic nanoplatform for osteoarthritis. J Nanobiotechnology. 2020;18:117. [DOI] [PubMed] [PMC]

113.

Srinivasan S, Kumar R, Koduru S, Chandramouli A, Damodaran C. Inhibiting TNF-mediated signaling: a novel therapeutic paradigm for androgen independent prostate cancer. Apoptosis. 2010;15:153–61. [DOI] [PubMed] [PMC]

114.

Kumar R, Srinivasan S, Pahari P, Rohr J, Damodaran C. Activating stress-activated protein kinase-mediated cell death and inhibiting epidermal growth factor receptor signaling: a promising therapeutic strategy for prostate cancer. Mol Cancer Ther. 2010;9:2488–96. [DOI] [PubMed] [PMC]

115.

Szliszka E, Czuba ZP, Sêdek Ł, Paradysz A, Król W. Enhanced TRAIL-mediated apoptosis in prostate cancer cells by the bioactive compounds neobavaisoflavone and psoralidin isolated from Psoralea corylifolia. Pharmacol Rep. 2011;63:139–48. [DOI]

116.

Das TP, Suman S, Damodaran C. Induction of reactive oxygen species generation inhibits epithelial-mesenchymal transition and promotes growth arrest in prostate cancer cells. Mol Carcinog. 2014;53:537–47. [DOI] [PubMed] [PMC]

117.

Pal D, Suman S, Kolluru V, Sears S, Das TP, Alatassi H, et al. Inhibition of autophagy prevents cadmium-induced prostate carcinogenesis. Br J Cancer. 2017;117:56–64. [DOI] [PubMed] [PMC]

118.

Bronikowska J, Szliszka E, Jaworska D, Czuba ZP, Krol W. The coumarin psoralidin enhances anticancer effect of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Molecules. 2012;17:6449–64. [DOI] [PubMed] [PMC]

119.

Hao W, Zhang X, Zhao W, Chen X. Psoralidin induces autophagy through ROS generation which inhibits the proliferation of human lung cancer A549 cells. PeerJ. 2014;2:e555. [DOI]

120.

Ren G, Luo W, Sun W, Niu Y, Ma D, Leung C, et al. Psoralidin induced reactive oxygen species (ROS)-dependent DNA damage and protective autophagy mediated by NOX4 in breast cancer cells. Phytomedicine. 2016;23:939–47. [DOI] [PubMed]

121.

Jin Z, Yan W, Jin H, Ge C, Xu Y. Psoralidin inhibits proliferation and enhances apoptosis of human esophageal carcinoma cells via NF-κB and PI3K/Akt signaling pathways. Oncol Lett. 2016;12:971–6. [DOI] [PubMed] [PMC]

122.

Jin Z, Yan W, Jin H, Ge C, Xu Y. Differential effect of psoralidin in enhancing apoptosis of colon cancer cells via nuclear factor-κB and B-cell lymphoma-2/B-cell lymphoma-2-associated X protein signaling pathways. Oncol Lett. 2016;11:267–72. [DOI] [PubMed] [PMC]

123.

Sun C, Zhao L, Wang X, Hou Y, Guo X, Lu J, et al. Psoralidin, a natural compound from Psoralea corylifolia, induces oxidative damage mediated apoptosis in colon cancer cells. J Biochem Mol Toxicol. 2022;36:e23051. [DOI] [PubMed]

124.

Yu B, Wang A, Zhou K, Chai L, Liu L. Molecular Pathway of Psoralidin-Induced Apoptosis in HepG2 Cell Line. Chin J Integr Med. 2019;25:757–62. [DOI] [PubMed]

125.

Li J, Fu Y, Hu X, Xiong Y. Psoralidin inhibits the proliferation of human liver cancer cells by triggering cell cycle arrest, apoptosis and autophagy and inhibits tumor growth in vivo. J BUON. 2019;24:1950–5. [PubMed]

126.

Cheng S, Liu S, Chen B, Du C, Xiao P, Luo X, et al. Psoralidin inhibits osteosarcoma growth and metastasis by downregulating ITGB1 expression via the FAK and PI3K/Akt signaling pathways. Chin Med. 2023;18:34. [DOI] [PubMed] [PMC]

127.

Collin F. Chemical Basis of Reactive Oxygen Species Reactivity and Involvement in Neurodegenerative Diseases. Int J Mol Sci. 2019;20:2407. [DOI] [PubMed] [PMC]

128.

Sies H, Jones DP. Reactive oxygen species (ROS) as pleiotropic physiological signalling agents. Nat Rev Mol Cell Biol. 2020;21:363–83. [DOI] [PubMed]

129.

Krylatov AV, Maslov LN, Voronkov NS, Boshchenko AA, Popov SV, Gomez L, et al. Reactive Oxygen Species as Intracellular Signaling Molecules in the Cardiovascular System. Curr Cardiol Rev. 2018;14:290–300. [DOI] [PubMed] [PMC]

130.

Snezhkina AV, Kudryavtseva AV, Kardymon OL, Savvateeva MV, Melnikova NV, Krasnov GS, et al. ROS Generation and Antioxidant Defense Systems in Normal and Malignant Cells. Oxid Med Cell Longev. 2019;2019:6175804. [DOI] [PubMed] [PMC]

131.

Rotariu D, Babes EE, Tit DM, Moisi M, Bustea C, Stoicescu M, et al. Oxidative stress - Complex pathological issues concerning the hallmark of cardiovascular and metabolic disorders. Biomed Pharmacother. 2022;152:113238. [DOI] [PubMed]

132.

Aggarwal V, Tuli HS, Varol A, Thakral F, Yerer MB, Sak K, et al. Role of Reactive Oxygen Species in Cancer Progression: Molecular Mechanisms and Recent Advancements. Biomolecules. 2019;9:735. [DOI] [PubMed] [PMC]

133.

Nakamura H, Takada K. Reactive oxygen species in cancer: Current findings and future directions. Cancer Sci. 2021;112:3945–52. [DOI] [PubMed] [PMC]

134.

Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35:495–516. [DOI] [PubMed] [PMC]

135.

Reed JC. Dysregulation of apoptosis in cancer. J Clin Oncol. 1999;17:2941–53. [DOI] [PubMed]

136.

Liu X, Ma H, Fei L, Jiang M, Xia M, Bai L, et al. HPV-mediated down-regulation of NOD1 inhibits apoptosis in cervical cancer. Infect Agent Cancer. 2020;15:6. [DOI] [PubMed] [PMC]

137.

Parzych KR, Klionsky DJ. An overview of autophagy: morphology, mechanism, and regulation. Antioxid Redox Signal. 2014;20:460–73. [DOI] [PubMed] [PMC]

138.

Guo F, Liu X, Cai H, Le W. Autophagy in neurodegenerative diseases: pathogenesis and therapy. Brain Pathol. 2018;28:3–13. [DOI] [PubMed] [PMC]

139.

Aman Y, Schmauck-Medina T, Hansen M, Morimoto RI, Simon AK, Bjedov I, et al. Autophagy in healthy aging and disease. Nat Aging. 2021;1:634–50. [DOI] [PubMed] [PMC]

140.

Hua Y, Zhang J, Liu Q, Su J, Zhao Y, Zheng G, et al. The Induction of Endothelial Autophagy and Its Role in the Development of Atherosclerosis. Front Cardiovasc Med. 2022;9:831847. [DOI] [PubMed] [PMC]

141.

Pang Y, Wu L, Tang C, Wang H, Wei Y. Autophagy-Inflammation Interplay During Infection: Balancing Pathogen Clearance and Host Inflammation. Front Pharmacol. 2022;13:832750. [DOI] [PubMed] [PMC]

142.

Lim SM, Hanif EAM, Chin S. Is targeting autophagy mechanism in cancer a good approach? The possible double-edge sword effect. Cell Biosci. 2021;11:56. [DOI] [PubMed] [PMC]

143.

Liang XH, Jackson S, Seaman M, Brown K, Kempkes B, Hibshoosh H, et al. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature. 1999;402:672–6. [DOI] [PubMed]

144.

Yue Z, Jin S, Yang C, Levine AJ, Heintz N. Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proc Natl Acad Sci U S A. 2003;100:15077–82. [DOI] [PubMed] [PMC]

145.

Xie X, White EP, Mehnert JM. Coordinate autophagy and mTOR pathway inhibition enhances cell death in melanoma. PLoS One. 2013;8:e55096. [DOI] [PubMed] [PMC]

146.

Zheng H, Zhang X, Wang X, Sun B. Autophagy enhances the aggressiveness of human colorectal cancer cells and their ability to adapt to apoptotic stimulus. Cancer Biol Med. 2012;9:105–10. [DOI] [PubMed] [PMC]

147.

Zhu W, Pan X, Li F, Zhang Y, Lu X. Expression of Beclin 1 and LC3 in FIGO stage I-II cervical squamous cell carcinoma and relationship to survival. Tumour Biol. 2012;33:1653–9. [DOI] [PubMed]

148.

Cheng H, Zhang Y, Wu Q, Sun X, Sun J, Huang X. Expression of beclin 1, an autophagy-related protein, in human cervical carcinoma and its clinical significance. Eur J of Gynaecol Oncol. 2012;33:15–20. [PubMed]

149.

Wang H, Yang G, Huang Y, Huang Q, Gao J, Zhao X, et al. Reduced expression of autophagy markers correlates with high-risk human papillomavirus infection in human cervical squamous cell carcinoma. Oncol Lett. 2014;8:1492–8. [DOI] [PubMed] [PMC]

150.

O’Brien CA, Kreso A, Jamieson CHM. Cancer stem cells and self-renewal. Clin Cancer Res. 2010;16:3113–20. [DOI] [PubMed]

151.

Vermeulen L, Todaro M, Mello FdS, Sprick MR, Kemper K, Alea MP, et al. Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc Natl Acad Sci U S A. 2008;105:13427–32. [DOI] [PubMed] [PMC]

152.

Moore N, Lyle S. Quiescent, slow-cycling stem cell populations in cancer: a review of the evidence and discussion of significance. J Oncol. 2011;2011:396076. [DOI] [PubMed] [PMC]

153.

Tomasetti C, Levy D. Role of symmetric and asymmetric division of stem cells in developing drug resistance. Proc Natl Acad Sci U S A. 2010;107:16766–71. [DOI] [PubMed] [PMC]

154.

Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367:645–8. [DOI] [PubMed]

155.

Huang T, Song X, Xu D, Tiek D, Goenka A, Wu B, et al. Stem cell programs in cancer initiation, progression, and therapy resistance. Theranostics. 2020;10:8721–43. [DOI] [PubMed] [PMC]

156.

Tripathi T, Yadav J, Janjua D, Chaudhary A, Joshi U, Senrung A, et al. Targeting Cervical Cancer Stem Cells by Phytochemicals. Curr Med Chem. 2024;31:5222–54. [DOI] [PubMed]

157.

Pal D, Kolluru V, Chandrasekaran B, Baby BV, Aman M, Suman S, et al. Targeting aberrant expression of Notch-1 in ALDH⁺ cancer stem cells in breast cancer. Mol Carcinog. 2017;56:1127–36. [DOI] [PubMed] [PMC]

158.

Suman S, Das TP, Damodaran C. Silencing NOTCH signaling causes growth arrest in both breast cancer stem cells and breast cancer cells. Br J Cancer. 2013;109:2587–96. [DOI] [PubMed] [PMC]

159.

Zhao D, Mo Y, Li M, Zou S, Cheng Z, Sun Y, et al. NOTCH-induced aldehyde dehydrogenase 1A1 deacetylation promotes breast cancer stem cells. J Clin Invest. 2014;124:5453–65. [DOI] [PubMed] [PMC]

160.

López J, Poitevin A, Mendoza-Martínez V, Pérez-Plasencia C, García-Carrancá A. Cancer-initiating cells derived from established cervical cell lines exhibit stem-cell markers and increased radioresistance. BMC Cancer. 2012;12:48. [DOI] [PubMed] [PMC]

161.

Chen D, Wu M, Li Y, Chang I, Yuan Q, Ekimyan-Salvo M, et al. Targeting BMI1⁺ Cancer Stem Cells Overcomes Chemoresistance and Inhibits Metastases in Squamous Cell Carcinoma. Cell Stem Cell. 2017;20:621–34.e6. [DOI] [PubMed] [PMC]

162.

Tonnesen MG, Feng X, Clark RA. Angiogenesis in wound healing. J Investig Dermatol Symp Proc. 2000;5:40–6. [DOI] [PubMed]

163.

Gerecht-Nir S, Osenberg S, Nevo O, Ziskind A, Coleman R, Itskovitz-Eldor J. Vascular development in early human embryos and in teratomas derived from human embryonic stem cells. Biol Reprod. 2004;71:2029–36. [DOI] [PubMed]

164.

Filindris T, Papakonstantinou E, Keramida M, Panteris E, Kalogeropoulos S, Georgopoulos N, et al. The effect of GnRH-a on the angiogenesis of endometriosis. Hormones (Athens). 2024. [DOI] [PubMed]

165.

Lugano R, Ramachandran M, Dimberg A. Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell Mol Life Sci. 2020;77:1745–70. [DOI] [PubMed] [PMC]

166.

Ancuţa C, Ancuţa E, Zugun-Eloae F, Carasevici E. Neoangiogenesis in cervical cancer: focus on CD34 assessment. Rom J Morphol Embryol. 2010;51:289–94. [PubMed]

167.

Senrung A, Tripathi T, Aggarwal N, Janjua D, Yadav J, Chaudhary A, et al. Phytochemicals Showing Antiangiogenic Effect in Pre-clinical Models and their Potential as an Alternative to Existing Therapeutics. Curr Top Med Chem. 2024;24:259–300. [DOI] [PubMed]

168.

Amani D, Shakiba E, Motaghi E, Alipanah H, Jalalpourroodsari M, Rashidi M. Psoralidin exerts anti-tumor, anti-angiogenic, and immunostimulatory activities in 4T1 tumor-bearing balb/c mice. Horm Mol Biol Clin Investig. 2021;43:71–9. [DOI] [PubMed]

169.

Li Y, Meng Q, Yang M, Liu D, Hou X, Tang L, et al. Current trends in drug metabolism and pharmacokinetics. Acta Pharm Sin B. 2019;9:1113–44. [DOI] [PubMed] [PMC]

170.

Liu Y, Flynn TJ. CYP3A4 inhibition by Psoralea corylifolia and its major components in human recombinant enzyme, differentiated human hepatoma HuH-7 and HepaRG cells. Toxicol Rep. 2015;2:530–4. [DOI] [PubMed] [PMC]

171.

Shi M, Cui Y, Liu C, Li C, Liu Z, Kang W. CYPs-mediated drug-drug interactions on psoralidin, isobavachalcone, neobavaisoflavone and daidzein in rats liver microsomes. Food Chem Toxicol. 2020;136:111027. [DOI] [PubMed]

172.

Piao S, Lin H, Tao X, Chen W. Mitochondrial toxicants in Xian-Ling-Gu-Bao induce liver injury by regulating the PI3K/mTOR signaling pathway: an in vitro study. BMC Complement Med Ther. 2022;22:317. [DOI] [PubMed] [PMC]

173.

Shi X, Zhang G, Mackie B, Yang S, Wang J, Shan L. Comparison of the in vitro metabolism of psoralidin among different species and characterization of its inhibitory effect against UDP- glucuronosyltransferase (UGT) or cytochrome p450 (CYP450) enzymes. J Chromatogr B Analyt Technol Biomed Life Sci. 2016;1029–1030:145–56. [DOI] [PubMed]

174.

Yang Y, Zhang Y, Chen Z, Zhang Y, Yang X. Plasma pharmacokinetics and cerebral nuclei distribution of major constituents of Psoraleae fructus in rats after oral administration. Phytomedicine. 2018;38:166–74. [DOI] [PubMed]

175.

Zhou Z, Yang L, Cheng L, Yu Y, Song L, Zhou K, et al. Simultaneous characterization of multiple Psoraleae Fructus bioactive compounds in rat plasma by ultra-high-performance liquid chromatography coupled with triple quadrupole mass spectrometry for application in sex-related differences in pharmacokinetics. J Sep Sci. 2020;43:2804–16. [DOI] [PubMed]

176.

Yin J, Xiang C, Song X. Nanoencapsulation of psoralidin via chitosan and Eudragit S100 for enhancement of oral bioavailability. Int J Pharm. 2016;510:203–9. [DOI] [PubMed]

177.

Sharifi-Rad J, Kamiloglu S, Yeskaliyeva B, Beyatli A, Alfred MA, Salehi B, et al. Pharmacological Activities of Psoralidin: A Comprehensive Review of the Molecular Mechanisms of Action. Front Pharmacol. 2020;11:571459. [DOI] [PubMed] [PMC]

178.

Mattheolabakis G, Rigas B, Constantinides PP. Nanodelivery strategies in cancer chemotherapy: biological rationale and pharmaceutical perspectives. Nanomedicine (Lond). 2012;7:1577–90. [DOI] [PubMed]

179.

Solanki R, Jodha B, Prabina KE, Aggarwal N, Patel S. Recent advances in phytochemical based nano-drug delivery systems to combat breast cancer: A review. J Drug Delivery Sci Technol. 2022;77:103832. [DOI]

180.

Youness RA, Al-Mahallawi AM, Mahmoud FH, Atta H, Braoudaki M, Fahmy SA. Oral Delivery of Psoralidin by Mucoadhesive Surface-Modified Bilosomes Showed Boosted Apoptotic and Necrotic Effects against Breast and Lung Cancer Cells. Polymers (Basel). 2023;15:1464. [DOI] [PubMed] [PMC]

181.

Conacher M, Alexander J, Brewer JM. Oral immunisation with peptide and protein antigens by formulation in lipid vesicles incorporating bile salts (bilosomes). Vaccine. 2001;19:2965–74. [DOI] [PubMed]